Sterile Single-Use Syringes: GB 15810 Test Submission Essentials

First confirm whether GB 15810 applies to the syringe in front of you

In a testing context, "single-use syringe" is never a single object. Before writing a test list, place the product with three questions, in this order.

Question one: is it supplied sterile? GB 15810 applies to single-use syringes supplied in a sterile state. The whole cluster of requirements around sterility, bacterial endotoxins, sterilisation process validation, sterile barrier packaging and shelf life rests on the premise that the product leaves the factory sterile. If the product ships non-sterile and is processed at the point of use, or is supplied only as a component for downstream integration, that entire cluster falls away, and you have to go back to the intended use of the product to establish which standard applies - checking sentence by sentence against the scope clause in the current valid version of the standard text rather than assuming it from the product name. This question comes first because what it decides is not whether one test is performed but the skeleton of the whole list.

Question two: is it supplied with a needle? For products supplied with a needle, the accompanying hypodermic needle has its own applicable product standard and its own tests - stiffness and toughness of the tube, penetration performance of the point, and strength of the joint between hub and tube are all governed by the needle-side standard and cannot be assumed to be covered by testing on the syringe body. Which standard is cited and which edition applies has to be confirmed against the current valid version of the standard text and the actual configuration of the product. Where no needle is supplied, the connection path is evaluated only for the fit between the conical fitting and the external interface.

Question three: is it an auto-disable, prefilled or other special type? Auto-disable designs add a set of verifications for functional effectiveness and prevention of reuse. Prefilled designs coexist with a drug solution for the whole shelf life, so compatibility and stability considerations are entirely different from an empty syringe, and requirements from the drug side often apply in parallel. Whether these types remain within the scope of GB 15810, and which additional requirements stack on top, again has to be confirmed against the scope clause of the current valid version rather than inferred from experience with similar products.

Only once all three questions are answered is it meaningful to write a test list. Quoting and shipping samples before this step is settled often means the entire list has to be scrapped.

Failure paths specific to syringes: sliding, connection, dosing

Build the list by working backwards from the use path rather than reading the standard's contents page from the top. A syringe performs only a handful of actions clinically: drawing up, expelling air, connecting, and injecting. Expand those actions and several independent paths appear, and the corrective action behind each is completely different - sliding and connection problems mean tooling and assembly changes, dosing problems mean moulding and scale printing changes, contact-surface problems mean raw material and process changes.

Use the table this way: tick or strike out each row against the actual structure of your product, then write the reason next to each struck-out row - for example, "supplied without a needle, so the connection path is evaluated only for the fit between the conical fitting and the infusion connector". That annotated list is a useful page of submission material in its own right, and it avoids having to improvise an explanation when a reviewer asks why an item was omitted. The reasoning about failure paths below is an engineering analysis based on structural and material characteristics, not a statistical conclusion about failure rates; specific acceptance requirements are governed by the current valid version of the standard text.

Sliding performance and barrel tightness: two indicators that pull against each other

These two are a classic conflict on a syringe. Silicone oil coating weight and distribution, hardness and interference of the plunger stopper, and moulding quality of the barrel bore - the same set of structural conditions decides both ends simultaneously. Make the seal tight and sliding gets heavy: break-loose and sustained forces both rise and the injection feel becomes draggy or even jerky. Make sliding smooth and tightness is easily lost under pressure hold. Once the trade-off point is fixed during development, the two should not be optimised separately at the testing stage.

A common mistake at submission is to split the two tests across different batches and different sample states: sliding performance measured on freshly produced samples where the silicone distribution is still even, tightness measured on another batch that has been stored for a while. Each passes individually, but no single batch of samples ever demonstrates that both hold in the same state - and clinically it is the same syringe that has to do both. The sound approach is to cover both with samples from the same batch in the same state, and to record the post-assembly storage state and any preconditioning on the test request form.

Discrepancies on retest cluster here too: whether the push-pull rate is controlled, the orientation in which samples were stored before testing, and migration of silicone oil and compression set of the stopper after assembly can all make the same batch give different results at different points in time. None of these is a product defect - they are states that were never agreed.

The dosing chain: scale, capacity tolerance and dead space

These three are often treated as unrelated tests when in fact they sit on one dosing chain. The moulded or printed position of the scale has a tolerance; which edge of the plunger front face is taken as the reading datum is understood differently by different parties; and the geometry of the conical fitting bore together with the plunger front face determines the volume of drug left inside after full depression. An inconsistent definition anywhere on that chain can make a capacity tolerance retest fail to reconcile - and the dispute is usually not about measurement accuracy but about the two sides reading against different datums.

The workable fix is simple: write "which edge of the plunger is taken as the reading datum" and "by what technique dead space is expelled" into the work instruction, align once with the laboratory before submission, and supply the scale printing drawing and the plunger section drawing with the samples. This takes very little effort and heads off most later arguments about dosing.

The conical fitting and the needle hub (or infusion connector)

The conical fitting is the critical interface between the syringe and external devices, and it carries out both sealing and retention, so its failure modes come in two kinds: axial pull-off and rotational loosening belong to joint strength, while leakage at the interface belongs to liquid tightness. A fitting with a rotational locking feature and a purely friction-fit fitting are loaded differently and are judged differently, so data from one cannot stand in for the other.

Interchangeable dimensions and performance requirements for conical fittings are set by the general interface standard; which one is cited and which edition applies has to be confirmed against the current valid version of the standard text and the actual interface type of the product, rather than assumed from a habitual name. What has to be stated at submission is what the mating part was - the matching needle hub, an infusion set connector, or a reference gauge - because conclusions obtained with different mating parts cannot be extrapolated to one another.

Drug contact and chemical tests: draw the contact boundary first

The chemical analysis methods themselves are set by GB/T 14233 and are not complicated. What actually determines the result is how the extraction object and extraction conditions map onto the product: does the fluid path contact boundary include the whole plunger rod, should a needle be extracted along with the syringe on a needled product, was the blank control processed under the same conditions as the samples, and was sampling for ethylene oxide residues scheduled after aeration was complete. These are generic methodology questions; we cover extraction logic and how the chemical and biological lines connect in a separate article and will not expand on them here.

On the syringe side, the submitting party only has to nail down two things. First, use a drawing in the accompanying documentation to define the fluid path contact boundary explicitly (whether the barrel bore, the plunger front face and the conical fitting bore are each included). Second, declare that the submitted samples are finished products that have been through the complete sterilisation and aeration process, and that the raw material grades, masterbatch, mould release agent and silicone oil coating process are all identical to routine production. With those two written down, the extraction plan has something to stand on.

Biological evaluation, sterilisation and packaging: what a syringe has to state additionally

Biological evaluation follows the route of the ISO 10993 series (the domestic counterpart being the GB/T 16886 series): the evaluation process and the choice of test combination follow ISO 10993-1, the cytotoxicity test method follows ISO 10993-5, and the remaining endpoints follow the corresponding parts of the series - which part governs and which edition applies has to be confirmed against the current valid version of the standard text and your evaluation route. How the evaluation route unfolds is not a syringe-specific issue; see the biocompatibility testing service description. There is only one point a syringe has to state additionally: silicone oil is both the key variable in sliding performance and an input to biological evaluation, so changing silicone grade or coating process in routine production means the evaluation has to be repeated.

Sterilisation and packaging work the same way. Process validation for ethylene oxide sterilisation follows ISO 11135; process validation for sterile barrier packaging, packaging performance and shelf life stability follow ISO 11607; other sterilisation methods follow the process validation standard applicable to that method, with the standard number confirmed against the current valid version. For the general approach see sterilisation validation and packaging validation. What is particular about a syringe is the structure: the cavity formed once the plunger rod and barrel are assembled is a relatively closed space, so loading configuration and aeration conditions affect residues more than they would on a solid part of similar external shape. The loading configuration used for sterilisation validation therefore has to match routine production, and the packaging submitted for testing has to match the marketed form.

Settle these things before submission

Almost nobody forgets the samples. What gets forgotten is the accompanying documentation and the agreed sample state. The table below can be used directly as a checklist.

The cost of a tight sample count is routinely underestimated: once a result lands on the acceptance boundary with no samples left to retest, you have to schedule production again, sterilise again and submit again. For general sample and documentation requirements, start with testing requirements; this article lists only what a syringe has to state on top of that.

Common reasons syringe projects get sent back

In our experience, rejections cluster in a few categories: sliding performance and barrel tightness submitted on different batches in different states; specification coverage merging different conical fitting types into one group with no rationale; reading datum and expulsion technique not aligned with the laboratory, so capacity tolerance retests fail to reconcile; submitted samples that are not finished products through the complete sterilisation and aeration process; auto-disable types submitted with a structural description only, missing verification data for functional effectiveness and prevention of reuse; silicone oil or masterbatch changed in routine production without repeating the biological evaluation; and packaging submitted for testing that differs from the actual marketed packaging.

These all share one feature - none of them is a product performance failure. They are problems of submission state and of internal consistency in the documentation, and most can be avoided before the samples ship. What genuinely requires a design change is usually limited to structural issues such as the sliding-versus-tightness trade-off and conical fitting joint strength, and those have normally already surfaced once during development verification.

A note on accreditation and report use

SUNGO Lab (Shanghai Shage Medical Technology Co., Ltd.) is accredited by CNAS, CMA and IAS (USA) and operates laboratories in Shanghai and Hefei. To be explicit: an accreditation mark only demonstrates that the laboratory has the technical competence within its accredited scope and does not constitute a commitment regarding market access outcomes. Whether a product may be marketed in a given market depends on the competent authority's review of the complete submission dossier, of which a test report is only one part.

Applying the list to your own product

If you are preparing registration testing or export testing for sterile single-use syringes, we can start by placing the product with the three questions above, then build the GB 15810 and GB/T 14233 test list, the biological evaluation route and the sterilisation and packaging validation plan around your structure and target market, and finally fix sample quantities, batch arrangements and submission dates so that split shipments do not create repeated queuing. Our Shanghai and Hefei laboratories handle physical, chemical, biological and packaging-related testing for syringes and related single-use sterile devices.

To build the list or to discuss lead time and cost, call +86 132 4819 8029, or request a quote directly.